Skip to main content

AMCAL WILD KRILL 1000, Sigma Healthcare Limited, CON-301

Product name
AMCAL WILD KRILL 1000
Sponsor name
Sigma Healthcare Limited
ARTG
205899
Consent start
Consent no.
CON-301
Standard
United States Pharmacopeia-National Formulary (USP41-NF36) monograph for Krill Oil
Non-compliance with standard
The products do not comply with the of the United States Pharmacopeia-National Formulary (USP41-NF36) monograph for Krill Oil (Euphausia superba oil; referred to hereinafter as 'raw material') used in the manufacture of theproducts.
Conditions imposed
Consent is given to import and supply the raw material and the products on the condition that the raw material meets the limits as set out in the table belowTable 1 Imposed limits for Krill oil raw materialTestLimits1.Identification test A-Fatty acid profile Myristic acid5.0-13.0%Oleic acid6.0-14.5%Eicosapentanoic acid14.0-28.0%2.Ratio between fatty acids Palmitic acid and myristic acid1.6-3.6%3.Content of AstraxanthinAstraxanthinNot less than 0.005%4.Content of total lipidsSum of Sum of phosphatidylcholine, 1-lysophosphatidylcholine, and 2-lysophosphatidylcholine-60-90%The above limits are consistent with the proposed revision in the Second Supplement to USP41-NF36 monograph for Krill oil.
Therapeutic product type
Listed complementary medicines

Help us improve the Therapeutic Goods Administration site